A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT ID
NCT07018700
Registry status
Recruiting
Study type
Interventional
Phase
Phase 3
Sponsor
Merz Therapeutics GmbH
Conditions
Episodic Migraine

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine

Enrollment: 990 participants (Estimated).

What is being studied

  • Intervention: Amino Acids, Peptides, and Proteins
  • Intervention: Bacterial Proteins
  • Intervention: Bacterial Toxins
  • Intervention: Biological Factors
  • Intervention: Botulinum Toxins
  • Intervention: Botulinum Toxins, Type A
  • Intervention: Endopeptidases
  • Intervention: Enzymes
  • Intervention: Enzymes and Coenzymes
  • Intervention: Hydrolases
  • Intervention: incobotulinumtoxinA
  • Intervention: Metalloendopeptidases
  • Intervention: Metalloproteases
  • Intervention: Peptide Hydrolases
  • Drug: Placebo
  • Intervention: Proteins
  • Intervention: Toxins, Biological
  • Drug: Xeomin

Who may be eligible

Ages
18 Years to no maximum
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Participant has a diagnosis of EM with or without aura according to current International Classification of Headache Disorders (Edition 3 and Edition 4 alpha) criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches; * Participant age \< 50 years at the time of migraine onset; * Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≤ 14 headache days per month and history of 6 to 14 migraine days per month; and * During the last 28 days of the screening period, participant experiencing: ≤ 14 headache days and 6 to 14 migraine days that qualify as such per the headache diary. Exclusion Criteria: * Diagnosis of chronic migraine; * Diagnosis of other primary headache types, except tension-type headache, which is permitted; * Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction; * Diagnosis of secondary headache types, except medication overuse headache, which is permitted; * Currently taking \> 1 prescribed drug for the preventive treatment of migraine; * Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.

Study locations

110 study locations are listed.

Recruiting site status is explicitly provided for 110 locations; 110 are listed as Recruiting.

Countries: Austria, Canada, Czechia, Denmark, France, Germany, Italy, Poland, Slovakia, Spain, Switzerland, United Kingdom, United States

  • Arizona, United States: 2
  • Arkansas, United States: 1
  • California, United States: 4
  • Connecticut, United States: 3
  • Florida, United States: 6
  • Georgia, United States: 1
  • Hawaii, United States: 1
  • Kansas, United States: 1
  • Louisiana, United States: 2
  • Maryland, United States: 1
  • Massachusetts, United States: 2
  • Michigan, United States: 2
  • Minnesota, United States: 1
  • Missouri, United States: 1
  • Nebraska, United States: 1
  • New York, United States: 6
  • Ohio, United States: 3
  • Oklahoma, United States: 1
  • Pennsylvania, United States: 1
  • South Carolina, United States: 1
  • Texas, United States: 2
  • Virginia, United States: 2
  • Washington, United States: 1
  • Wisconsin, United States: 1

Sample of listed locations

  • Medical University of Innsbruck, Merz Investigational Site #0430043 — Innsbruck, 6020, Austria — Recruiting
  • Klinikum Klagenfurt Am Wörthersee, Merz Investigational Site #0430042 — Klagenfurt, 9020, Austria — Recruiting
  • Genge Partners Inc., Merz Investigational Site #0010525 — Montreal, H4A 3T2, Canada — Recruiting
  • CaRe Clinic, Merz Investigational Site #0010504 — Red Deer, T4P 1K4, Canada — Recruiting
  • Pratia Brno, Merz Investigational Site #4200053 — Brno, 602 00, Czechia — Recruiting
  • Fakultní nemocnice Hradec Králové, Merz Investigational Site #4200056 — Hradec Králové, 500 05, Czechia — Recruiting
  • Axon Clinical, Merz Investigational Site #4200051 — Prague, 150 00, Czechia — Recruiting
  • CLINTRIAL, Merz Investigational Site #4200052 — Prague, 100 00, Czechia — Recruiting
  • Neuropsychiatrie, Merz Investigational Site #4200054 — Prague, 160 00, Czechia — Recruiting
  • Rigshospitalet-Glostrup, Merz Investigational Site #0450006 — Glostrup Municipality, 2600, Denmark — Recruiting
  • CHU Clermont Ferrand, Merz Investigational Site #0330026 — Clermont-Ferrand, 63000, France — Recruiting
  • Centre Hospitalier Universitaire Grenoble Alpes, Merz Investigational Site #0330069 — La Tronche, 38700, France — Recruiting
  • CHU Nantes, Merz Investigational Site #0330068 — Nantes, 44093, France — Recruiting
  • Charité - Universitätsmedizin Berlin, Merz Investigational Site #0490398 — Berlin, 10117, Germany — Recruiting
  • Kopfschmerzzentrum Frankfurt, Merz Investigational Site #0490394 — Frankfurt, 65929, Germany — Recruiting
  • Universitätsmedizin Greifswald, Merz Investigational Site #0490397 — Greifswald, 17475, Germany — Recruiting
  • Vitos Orthopädische Klinik Kassel, Merz Investigational Site #0490396 — Kassel, 34131, Germany — Recruiting
  • Schmerzklinik Kiel GmbH, Merz Investigational Site #0490395 — Kiel, 24149, Germany — Recruiting
  • Azienda Ospedaliera Universitaria Careggi, Merz Investigational Site #0390023 — Florence, 50134, Italy — Recruiting
  • Istituto Auxologico Italiano, Merz Investigational Site #0390024 — Milan, 20149, Italy — Recruiting
  • Ospedale San Raffaele, Merz Investigational Site #0390027 — Milan, 20132, Italy — Recruiting
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino, Merz Investigational Site #0390025 — Pavia, 27100, Italy — Recruiting
  • IRCCS San Raffaele Roma, Merz Investigational Site #0390026 — Roma, 00166, Italy — Recruiting
  • AthleticoMed, Merz Investigational Site #0480127 — Bydgoszcz, 85-752, Poland — Recruiting
  • Centrum Medyczne Neuromed, Merz Investigational Site #0480117 — Bydgoszcz, 85-163, Poland — Recruiting

Study details

Start date
August 21, 2025
Primary completion date
March 1, 2027
Completion date
October 1, 2027
First posted
June 12, 2025

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07018700
Registry last updated
September 25, 2026
QualifiedStudies registry data refreshed
October 5, 2026
QualifiedStudies record fetched
October 5, 2026

View NCT07018700 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Migraines studies | Clinical trial FAQ